Asset Details
Do you wish to reserve the book?
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
Do you wish to request the book?
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
2017
Overview
In prostate cancer, resistance to the antiandrogen enzalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR). In contrast to fixed genomic alterations, here we show that GR-mediated antiandrogen resistance is adaptive and reversible due to regulation of GR expression by a tissue-specific enhancer. GR expression is silenced in prostate cancer by a combination of AR binding and EZH2-mediated repression at the GR locus, but is restored in advanced prostate cancers upon reversion of both repressive signals. Remarkably, BET bromodomain inhibition resensitizes drug-resistant tumors to Enz by selectively impairing the GR signaling axis via this enhancer. In addition to revealing an underlying molecular mechanism of GR-driven drug resistance, these data suggest that inhibitors of broadly active chromatin-readers could have utility in nuanced clinical contexts of acquired drug resistance with a more favorable therapeutic index.
Publisher
eLife Science Publications, Ltd,eLife Sciences Publications Ltd,eLife Sciences Publications, Ltd
Subject
/ Androgen Antagonists - pharmacology
/ Animals
/ Azepines
/ Chromatin Immunoprecipitation - methods
/ Cloning
/ Clustered Regularly Interspaced Short Palindromic Repeats
/ Drug Resistance, Neoplasm - drug effects
/ Drug Resistance, Neoplasm - physiology
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Kinases
/ Leukemia
/ Male
/ Metabolism, Inborn Errors - metabolism
/ Mice
/ Mutation
/ Nitriles
/ Oncology
/ Phenylthiohydantoin - analogs & derivatives
/ Phenylthiohydantoin - pharmacology
/ Prostatic Neoplasms - pathology
/ Receptors, Androgen - metabolism
/ Receptors, Glucocorticoid - deficiency
/ Receptors, Glucocorticoid - genetics
/ Receptors, Glucocorticoid - metabolism
/ resistance to targeted therapies
/ Signal Transduction - drug effects
/ Tumors
